Biosimilars

Brain Cancer

Neoadjuvant HER2+

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastrointestinal Cancer

Urothelial Cancer

Prostate Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Non-Hodgkin Lymphoma

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Hematologic Oncology

Immunotherapy in GU Cancers

Immunotherapy in Lung Cancer

Immunotherapy in Melanoma

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Oncology Nursing News

Pediatric Oncology

Special Reports in Personalized Cancer Care

Precision Medicine in Oncology®

Sarcomas/TGCT

Supportive Care

Michael R. Cook, MD, discusses real-world data associated with the utilization of bridging therapy prior to treatment with axicabtagene ciloleucel in patients with relapsed/refractory large B-cell lymphoma.

Dr Cook on Real-World Data With Bridging Therapy and Axi-Cel in Relapsed/Refractory LBCL

Andre Goy, MD, discusses outcomes with brexucabtagene autoleucel in patients with relapsed/refractory mantle cell lymphoma enrolled in the phase 2 ZUMA-2 trial and the expanded access ZUMA-18 study.


Dr Goy on Outcomes From An Expanded Access Study of Brexu-Cel in Relapsed/Refractory MCL

Idecabtagene vicleucel resulted in meaningful improvements in symptoms, functioning, overall health status, and health-related quality of life vs standard regimens in select patients with triple-class exposed relapsed/refractory multiple myeloma, according to updated data from the phase 3 KarMMa-3 trial.

Ide-Cel Provides HRQOL Benefits Over Standard Regimens in R/R Multiple Myeloma

Although the use of bridging therapy prior to treatment with axicabtagene ciloleucel did not improve efficacy or safety outcomes for patients with relapsed/refractory large B-cell lymphoma, responses to bridging therapy may be prognostic of favorable outcomes after axi-cel administration. 

Bridging Therapy Prior to Axi-Cel Produces Favorable Real-World Outcomes in R/R LBCL 

News

OncClub

All Oncology News

Pipeline Report

Media

Insights

Medical World News

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

The Talk

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

PER Events

Scientific Interchanges

State of the Science Summit / IPC

Webinars

Partners

Publications

Oncology Live®

Oncology Fellows

Supplements And Featured Publications

All Publications

CME/CE

Resources

Interactive Tools

Learning Modules

Presentations

Biomarker Consortium

Subscribe

Print Subscription

eNewsletter

Articles

Dana-Farber Cancer Institute is launching a first-of-its-kind, integrated clinic to increase early detection of precancerous conditions and to prevent cancer from arising in individuals at increased risk for the disease. 

Dana-Farber Launches New Centers to Detect and Intercept Cancer

Brexucabtagene autoleucel is safe and effective in real-world patients with relapsed/refractory mantle cell lymphoma, regardless of the presence of high-risk features. 

Brexu-Cel Induces Responses in Real-World Population of High-Risk R/R MCL

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

CancerNetwork.com

CGTlive.com

CureToday.com

OncNursingNews.com

TargetedOnc.com

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

Twitter

LinkedIn

Youtube

Spotlight

2024 nominations are open for Giants of Cancer Care® 

In-person and virtual events just for HCPs

REGISTER TODAY to explore data on a novel second-generation BTK inhibitor for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Share your views with OncChats 

Specialty

Continuing Education

2023 Friday Satellite Symposia: Preceding the 65th ASH Annual Meeting and Exposition

Reflective Case-Based Oncology Collective: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care

Erika P. Hamilton, MD; Benjamin P. Levy, MD

Burst CME™ - Part II – Advent of HER3 Targeted Approaches and Rationale in NSCLC Care

Burst CME™ - Part I – Overview of Pathophysiology, Diagnosis, and Management of HER3 Expressing Cancers

Burst CME™ - Part III – Advent of HER3 Targeted Approaches and Rationale in Breast Cancer Care

Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat

Andre H. Goy, MD; Lorenzo Falchi, MD; Lori A. Leslie, MD; Michael L. Wang, MD

Bridging Clinical Gaps in Indolent and Aggressive B-Cell Lymphomas: The Investigators Demonstrate How Novel Mechanisms Will Impact Your Practice Tomorrow

William G. Wierda, MD, PhD; Jennifer R. Brown, MD, PhD; Ryan Jacobs, MD; Susan M. O’Brien, MD

Updates from the Annual Hematology Meeting: Matching the Tumor with Patient Specific Goals to Inform Frontline Selection and Sequencing in Chronic Lymphocytic Leukemia

Catherine C. Coombs, MD, MS; Lindsey Roeker, MD

Oncology Town Hall™: Primary Investigators Present Key Abstracts in the Management of CLL

Oncology Town Hall™: Primary Investigators Present Key Abstracts in Genitourinary Malignancies from Paris

Gregory J. Riely, MD, PhD; Erica Stumpf, MSN, NP-BC

Show Me Your Care Plan™: Monitoring and Managing Patients With EGFR Exon20 Insertion+ NSCLC

Joyce O’Shaughnessy, MD; Aditya Bardia, MD, MPH; Dejan Juric, MD; Lisa Newman, MD, MPH, FACS, FASCO; Priya Rastogi, MD

Medical Crossfire®: Clinical Decision-Making Under New Paradigms for HR+/HER2- Breast Cancer

Genovefa Papanicolaou, MD; Roy F. Chemaly, MD, MPH, FIDSA, FACP; Sanjeet Dadwal, MD, FACP, FIDSA; Guenther Koehne, MD, PhD

State-of-the-Art CMV Care: Experts’ Perspectives on Primary/Secondary Prevention and Management of Refractory/Resistant Infections

Loretta J. Nastoupil, MD; Ian W. Flinn, MD, PhD; Caron A. Jacobson, MD, MMSc; Jessica Okosun, MB BChir, PhD 

Follicular Lymphoma Workshop: Forging Patient-Centric Plans with Targeted Therapies Across Lines of Care

Advances In™: Meeting Unmet Clinical Needs in TNBC and HR+ Breast Cancer with TROP2-Targeted Regimens

Tabitha M. Cooney, MD; Scott L. Coven, DO, MPH; Jason R. Fangusaro, MD 

Evolving Evidence in Pediatric Brain Cancer: Spotlight on MAPK Inhibitors

Bernd Kasper, MD, PhD; Mrinal M. Gounder, MD

Advances In™ Desmoid Tumors: Recognizing Disease Burden, Pathophysiology, and Targeted Treatments in Development

Claire N. Harrison, DM, FRCP, FRCPath; Abdulraheem Yacoub, MD

Cancer Summaries and Commentaries™: Report from New Orleans on the Latest Updates in the Treatment of MPNs

Lori J. Wirth, MD; Benjamin J. Gigliotti, MD

 Addressing Clinical Gaps in Thyroid Cancer Management: Taking Action with Precision Methods to Personalize Treatment Decision-Making

Jacob Sands, MD; Zev A. Wainberg, MD; Aditya Bardia, MD, MPH

Medical Crossfire®: Antibody-Drug Conjugates Coming to Your Oncology Practice Tomorrow

Sara M. Tolaney, MD, MPH; Paolo Tarantino, MD

Oncology Consultations®: Clinical Impact of HER2-Low Expressing Breast Cancer and Novel Targeted Therapies to Address Unmet Needs in Care

Verena Staedtke, MD, PhD; Matthias A. Karajannis, MD, MS; Shannon Langmead, RN, MSN, CRNP, CNRN

Medical Crossfire®: What Strategies Can the Care Team Implement to Optimize the Management of Pediatric Patients with NF1?

Nikolai A. Podoltsev, MD, PhD; John Mascarenhas, MD

Oncology Consultations®: Leveraging Clinical Data and Trials to Inform Treatment for Patients with PV

Elias Jabbour, MD; Sabina Chiaretti, MD, PhD; Hagop M. Kantarjian, MD; Rob Pieters, MD, PhD; Bijal Shah, MD, MS 

 How The Experts Treat Acute Lymphoblastic Leukemia: Case Discussions from Adolescent to Adult

Corey Cutler, MD, MPH, FRCPC; Sergio Giralt, MD, FACP, FASTCT; Catherine Lee, MD; Doris M. Ponce, MD

Medical Crossfire®: How Do We Apply the Latest Evidence on Novel Therapies to Prevent and Treat GVHD?

C. Ola Landgren, MD, PhD; Aaron C. Logan, MD, PhD; Paolo Ghia, MD; Reid W. Merryman, MD

MRD Assessment as a Cornerstone to Clinical Decision-Making in Hematologic Malignancies: Techniques, Utilization, and Best Practices to Optimize Patient Outcomes

GU Tumor Board®: Real World Strategies to Inform Individualized Care in Renal Cell Carcinoma

Andrew Kuykendall, MD; Marina Kremyanskaya MD, PhD; Lucia Masarova, MD; Douglas A. Tremblay, MD

 How We Do It: Application of State-of-the-Art MF and PV Care Today… With An Eye Toward How New Evidence and Combinations Will be Leveraged Tomorrow

Joyce O’Shaughnessy, MD; Terry Mamounas, MD, MPH; Hope S. Rugo, MD, FASCO; Sara M. Tolaney, MD, MPH

School of Breast Oncology® Live Video Webcast: Clinical Updates From San Antonio

Anne Chiang, MD, PhD, FASCO; Balazs Halmos, MD, MS; Mark G. Kris, MD; Zofia Piotrowska, MD, MHS

Community Practice Connections™: 17th Annual New York Lung Cancers Symposium

Mapping Out the Role of Emerging Biomarkers and Testing in NSCLC

Laura Vaughan, RN, BSN; Abdulraheem Yacoub, MD

Oncology Consultations®: Determining Treatment-Related Adverse Events from Disease Progression Along the MPN Care Continuum

Ajai Chari, MD; Benjamin P. Levy, MD; Daniel P. Petrylak, MD; Diane Reidy-Lagunes, MD; Tiffany A. Traina, MD

 40th Annual CFS®: Innovative Cancer Therapy for Tomorrow®  

Trekking Through the Latest Updates for ROS1-Targeted Therapies

Naveen Pemmaraju, MD; Monica L. Guzman, PhD; Andrew A. Lane, MD, PhD; Muzaffar H. Qazilbash, MD

 Multidisciplinary Management of BPDCN: Strategies for Differential Diagnosis and Integrating Novel Targeted Therapy

Charu Aggarwal, MD, MPH; Heather A. Parsons, MD, MPH; John H. Strickler, MD

Community Practice Connections™: 6th Annual Precision Medicine Through Plasma™ – Using Liquid Biopsies in Contemporary Oncology Care 

Joyce O’Shaughnessy, MD; Aditya Bardia, MD, MPH; Priya Rastogi, MD


Community Practice Connections™: Clinical Decision Making Under New Paradigms for HR+/HER2-Breast Cancer

Anna Halpern, MD; Jeanne M. Palmer, MD; Bart L. Scott, MD

Oncology Roundtable: Treating MF and PV in 2023

Navigating the Latest Data on NTRK-Targeted Therapies

Andrew J. Wagner, MD, PhD, William Tap, MD

 Bridging Unmet Needs for Patients with Soft Tissue Sarcoma: Progress Toward Individualization of Care

21st Annual Winter Lung Cancer Conference®

Sikander Ailawadhi, MD; Craig Cole, MD; Anita D'Souza, MD

Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes

Ajai Chari, MD; Carol Ann Huff, MD; Adriana Rossi, MD

Keeping Pace with Rapid Advancements in Multiple Myeloma Care

David J. Straus, MD; Sharon Castellino, MD, MSc; Joseph M. Connors, MD, CM; Pier Luigi Zinzani, MD, PhD

 Maximizing Our Clinical Practices in Hodgkin Lymphoma: Integration of Recent Data Sets in Real World Settings

 State-of-the-Art CMV Care: Experts’ Perspectives on Primary/Secondary Prevention and Management of Refractory/Resistant Infections

Christopher J. Sweeney, MBBS; Rana R. McKay, MD; Tian Zhang, MD, MHS

Expert Perspectives on Emerging CDK4/6 Inhibitor Strategies in Advanced Prostate Cancer Management Settings

William G. Wierda, MD, PhD; Jennifer R. Brown, MD, PhD; Ryan Jacobs, MD; Susan M. O'Brien, MD

Community Practice Connections™: Matching the Tumor With Patient-Specific Goals to Inform Frontline Selection and Sequencing in Chronic Lymphocytic Leukemia

James L.M. Ferrara, MD, DSc; Everett Meyer

Cancer Summaries and Commentaries™: Report from New Orleans on the Latest Updates in GvHD Prevention and Treatment

Paolo Ghia, MD; C. Ola Landgren, MD, PhD; Aaron C. Logan, MD, PhD; Reid W. Merryman, MD

 MRD Assessment as a Cornerstone to Clinical Decision-Making in Hematologic Malignancies: Techniques, Utilization, and Best Practices to Optimize Patient Outcomes

Christopher C. Dvorak, MD; Matthias A. Karajannis, MD, MS; 
Kara M. Kelly, MD; Jacqueline M. Kraveka, DO

Clinical Vignettes: Inaugural International Congress on Pediatric Oncology

Toni Choueiri, MD; Shuchi Gulati, MD, MSc; Sumanta Pal, MD, FASCO; Thomas Powles, MBBS, MRCP, MD

Upcoming CME Events & Activities

EVENTS

ACTIVITIES

Latest Conference Coverage